It is indicated for locally advanced or metastatic adult breast cancer patients with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (Her2) negative who have received two or more endocrine treatments and one chemotherapy in the metastatic setting and disease progression [33]. This evidence concerns the gene HR and breast cancer.